Compare CCIX & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCIX | FDMT |
|---|---|---|
| Founded | 2023 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.8M | 431.4M |
| IPO Year | 2024 | 2020 |
| Metric | CCIX | FDMT |
|---|---|---|
| Price | $10.68 | $8.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $34.29 |
| AVG Volume (30 Days) | 536.5K | ★ 744.2K |
| Earning Date | 11-07-2013 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | ★ $120,000.00 |
| Revenue This Year | N/A | $21,227.03 |
| Revenue Next Year | N/A | $161.87 |
| P/E Ratio | $42.69 | ★ N/A |
| Revenue Growth | N/A | ★ 605.88 |
| 52 Week Low | $10.30 | $2.24 |
| 52 Week High | $11.66 | $12.34 |
| Indicator | CCIX | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 61.47 | 52.40 |
| Support Level | $10.65 | $7.77 |
| Resistance Level | $10.69 | $8.25 |
| Average True Range (ATR) | 0.02 | 0.55 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 84.62 | 80.41 |
Churchill Capital Corp IX is a blank check company.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.